Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase EARLY_PHASE1 1Phase 1/2 1

Status

Recruiting 3Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Small Cell Lung Carcinoma 1Pleural Effusion, Malignant 1NSCLC 1Lung Neoplasms 1

Interventions

Specimen Handling 481pembrolizumab 454Magnetic Resonance Spectroscopy 419Carboplatin 321Cyclophosphamide 314Biopsy 272Cisplatin 264Radiotherapy 239Paclitaxel 226Gemcitabine 222Bevacizumab 212Nivolumab 189fludarabine 183venetoclax 172Drug Therapy 165Dexamethasone 157Blood Specimen Collection 156Oxaliplatin 154Injections 152Capecitabine 152Fluorouracil 144Docetaxel 142Standard of Care 136Radiosurgery 136Rituximab 125Pemetrexed 115durvalumab 113atezolizumab 110Leucovorin 110Radiation 105

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × sugemalimab × 1 year × Clear all
NCT06097962 2026-05-20

Safety and Efficacy of NK510 to Treat NSCLC

Base Therapeutics (Shanghai) Co., Ltd.

Phase EARLY_PHASE1 Recruiting
12 enrolled
Thoracic

Pleural Effusion, Malignant

NCT06217757 2026-05-05

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

Sichuan University

Phase 1/2 Recruiting
45 enrolled
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT07247227 2025-11-25

Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC

Peking Union Medical College

Phase NA Recruiting
150 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡